|
[1] FRIEDMAN SL,NEUSCHWANDER-TETRI BA,RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.
|
|
[2] YOUNOSSI ZM. Non-alcoholic fatty liver disease-A global public health perspective[J]. J Hepatol,2019,70(3):531-544.
|
|
[3] ESTES C,RAZAVI H,LOOMBA R,et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology,2018,67(1):123-133.
|
|
[4] MARRA F,SVEGLIATI-BARONI G. Lipotoxicity and the gutliver axis in NASH pathogenesis[J]. J Hepatol,2018,68(2):280-295.
|
|
[5] POISSON J,LEMOINNE S,BOULANGER C,et al. Liver sinusoidal endothelial cells:Physiology and role in liver diseases[J]. J Hepatol,2017,66(1):212-227.
|
|
[6] BLOMHOFF R,DREVON CA,ESKILD W,et al. Clearance of acetyl low density lipoprotein by rat liver endothelial cells. Implications for hepatic cholesterol metabolism[J]. J Biol Chem,1984,259(14):8898-8903.
|
|
[7] MIYAO M,KOTANI H,ISHIDA T,et al. Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression[J].Lab Invest,2015,95(10):1130-1144.
|
|
[8] HAMMOUTENE A,RAUTOU PE. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease[J]. J Hepatol,2019,70(6):1278-1291.
|
|
[9] FRANCQUE S,VERRIJKEN A,MERTENS I,et al. Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis[J]. Eur J Gastroenterol Hepatol,2010,22(12):1449-1457.
|
|
[10] SEIFALIAN AM,PIASECKI C,AGARWAL A,et al. The effect of graded steatosis on flow in the hepatic parenchymal microcirculation[J]. Transplantation,1999,68(6):780-784.
|
|
[11] IJAZ S,YANG W,WINSLET MC,et al. The role of nitric oxide in the modulation of hepatic microcirculation and tissue oxygenation in an experimental model of hepatic steatosis[J]. Microvasc Res,2005,70(3):129-136.
|
|
[12] GARCIA-LEZANA T,RAURELL I,BRAVO M,et al. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis[J]. Hepatology,2018,67(4):1485-1498.
|
|
[13] GONZALEZ-PAREDES FJ,HERNANDEZ MG,MORALES AD,et al. Contribution of cyclooxygenase end products and oxidative stress to intrahepatic endothelial dysfunction in early non-alcoholic fatty liver disease[J]. PLo S One,2016,11(5):e156650.
|
|
[14] PASARIN M,LA MURA V,GRACIA-SANCHO J,et al. Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD[J]. PLo S One,2012,7(4):e32785.
|
|
[15] TATEYA S,RIZZO NO,HANDA P,et al. Endothelial NO/cGMP/VASP signaling attenuates Kupffer cell activation and hepatic insulin resistance induced by high-fat feeding[J]. Diabetes,2011,60(11):2792-2801.
|
|
[16] SCHILD L,DOMBROWSKI F,LENDECKEL U,et al. Impairment of endothelial nitric oxide synthase causes abnormal fat and glycogen deposition in liver[J]. Biochim Biophys Acta,2008,1782(3):180-187.
|
|
[17] WINDER WW,HARDIE DG. Inactivation of acetyl-Co A carboxylase and activation of AMP-activated protein kinase in muscle during exercise[J]. Am J Physiol,1996,270(2 Pt1):e299-e304.
|
|
[18] ROEDIGER WE,HEMS R,WIGGINS D,et al. Inhibition of hepatocyte lipogenesis by nitric oxide donor:Could nitric oxide regulate lipid synthesis?[J]. IUBMB Life,2004,56(1):35-40.
|
|
[19] MASLAK E,ZABIELSKI P,KOCHAN K,et al. The liver-selective NO donor,V-PYRRO/NO,protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet[J]. Biochem Pharmacol,2015,93(3):389-400.
|
|
[20] KUS K,WALCZAK M,MASLAK E,et al. Hepatoselective Nitric Oxide(NO)donors,V-PYRRO/NO and V-PROLI/NO,in nonalcoholic fatty liver disease:A comparison of antisteatotic effects with the biotransformation and pharmacokinetics[J].Drug Metab Dispos,2015,43(7):1028-1036.
|
|
[21] WANG W,ZHAO C,ZHOU J,et al. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis[J]. PLo S One,2013,8(10):e76538.
|
|
[22] XIE G,WANG X,WANG L,et al. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats[J]. Gastroenterology,2012,142(4):918-927.
|
|
[23] FONTANA L,EAGON JC,TRUJILLO ME,et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans[J]. Diabetes,2007,56(4):1010-1013.
|
|
[24] COULON S,FRANCQUE S,COLLE I,et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease[J]. Cytokine,2012,59(2):442-449.
|
|
[25] COULON S,LEGRY V,HEINDRYCKX F,et al. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models[J]. Hepatology,2013,57(5):1793-1805.
|
|
[26] LEFERE S,van de VELDE F,HOORENS A,et al. Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine nonalcoholic fatty liver disease[J]. Hepatology,2019,69(3):1087-1104.
|
|
[27] KITADE M,YOSHIJI H,KOJIMA H,et al. Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis[J]. Mol Med Rep,2008,1(4):543-548.
|
|
[28] COULON S,HEINDRYCKX F,GEERTS A,et al. Angiogenesis in chronic liver disease and its complications[J]. Liver Int,2011,31(2):146-162.
|
|
[29] DELEVE LD. Liver sinusoidal endothelial cells in hepatic fibrosis[J]. Hepatology,2015,61(5):1740-1746.
|
|
[30] MATZ-SOJA M,GEBHARDT R. The many faces of Hedgehog signalling in the liver:Recent progress reveals striking cellular diversity and the importance of microenvironments[J]. J Hepatol,2014,61(6):1449-1450.
|
DownLoad: